Optimizing treatment outcomes in chronic hepatitis C: Management of non-response

Antiviral Therapy

Volumn 11, Issue 8, 2006, Pages 955-970

  Pol, Stanislas ^a   Bourlière, Marc ^b  

^a Inserm U 567 Hôpital Cochin ^*  (France)

^b HÔPITAL SAINT JOSEPH   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; AMANTADINE; ANALGESIC AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIFIBROTIC AGENT; ANXIOLYTIC AGENT; COLCHICINE; CONSENSUS INTERFERON; GAMMA1B INTERFERON; GRANULOCYTE COLONY STIMULATING FACTOR; GROWTH FACTOR; IBUPROFEN; INTERFERON; INTERLEUKIN 10; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PARACETAMOL; PAROXETINE; PEGINTERFERON; PEGINTERFERON ALPHA; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; PENTOXIFYLLINE; PROSTAGLANDIN; RECOMBINANT ERYTHROPOIETIN; RIBAVIRIN; SEDATIVE AGENT; SEROTONIN UPTAKE INHIBITOR; THYMOSIN ALPHA1; UNINDEXED DRUG;

ADJUVANT THERAPY; ANEMIA; ANXIETY; ANXIETY DISORDER; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; DEPRESSION; DISEASE COURSE; DISEASE SEVERITY; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG MECHANISM; DRUG WITHDRAWAL; FATIGUE; FLU LIKE SYNDROME; HEADACHE; HEMATOLOGIC DISEASE; HEMOLYTIC ANEMIA; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IRRITABILITY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FAILURE; LIVER FIBROSIS; LONG TERM CARE; LOW DRUG DOSE; MAINTENANCE THERAPY; MENTAL DISEASE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OPTIMAL DRUG DOSE; PATIENT COMPLIANCE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; PROPHYLAXIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; REMISSION; RETREATMENT; REVIEW; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VIRUS CELL INTERACTION;

ANTIVIRAL AGENTS; HEPATITIS C, CHRONIC; HUMANS; INTERFERONS; RIBAVIRIN; TREATMENT OUTCOME;

EID: 33845600834     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (116)

1. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347:975-982.
2. Hadziyannis SJ, Sette H, Jr., Morgan TR, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140:346-355.
3. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358:958-965.
4. Zeuzem S, Diago M, Gane E, et al. Peginterferon alfa-2a (40 kilodaltons) and ribavirin in patients with chronic hepatitis C and normal aminotransferase levels. Gastroenterology 2004; 127:1724-1732.
5. Zeuzem S, Pawlotsky J-M, Lukasiewicz E, et al. International, multicenter, randomized, controlled study comparing dynamically individualized versus standard treatment in patients with chronic hepatitis C. J Hepatol 2005; 43:250-257.
6. Davis GL, Esteban-Mur R, Rustgi V, et al. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group. N Engl J Med 1998; 339:1493-1499.
7. Poynard T, Marcellin P, Lee SS, et al. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet 1998; 352:1426-1432.
8. McHutchison JG, Gordon SC, Schiff ER, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 1998; 339:1485-1492.
9. Strader DB, Wright T, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C. Hepatology 2004; 39:1147-1171.
10. Strader DB, Seeff LB. The natural history of chronic hepatitis C infection. Eur J Gastroenterol Hepatol 1996; 8:324-328.
11. EASL International Consensus Conference on Hepatitis C. Paris, 26-28, February 1999, Consensus Statement. European Association for the Study of the Liver. J Hepatol 1999; 30:956-961.
12. Spiegel BM, Younossi ZM, Hays RD, Revicki D, Robbins S, Kanwal F. Impact of hepatitis C on health related quality of life: a systematic review and quantitative assessment. Hepatology 2005; 41:790-800.
13. Bernstein D, Kleinman L, Barker CM, Revicki DA, Green J. Relationship of health-related quality of life to treatment adherence and sustained response in chronic hepatitis C patients. Hepatology 2002; 35:704-708.
14. Camma C, Di Bona D, Schepis F, et al. Effect of peginterferon alfa-2a on liver histology in chronic hepatitis C: a meta-analysis of individual patient data. Hepatology 2004; 39:333-342.
15. Gish R, Bzowej N, Brooks L, Brass C, Weng W. Treatment with pegylated interferon alfa-2b in combination with ribavirin improved health-related quality of life compared with interferon alfa-2b plus ribavirin in chronic hepatitis C. Hepatology 2002; 36:582A.
16. Hassanein T, Cooksley G, Sulkowski M, et al. The impact of peginterferon alfa-2a plus ribavirin combination therapy on health-related quality of life in chronic hepatitis C. J Hepatol 2004; 40:675-681.
17. Heathcote EJ, Shiffman ML, Cooksley WG, et al. Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. N Engl J Med 2000; 343:1673-1680.
18. Lee SS, Heathcote EJ, Reddy KR, et al. Prognostic factors and early predictability of sustained viral response with peginterferon alfa-2a (40 KD). J Hepatol 2002; 37:500-506.
19. Perrillo R, Rothstein KD, Rubin R, et al. Comparison of quality of life, work productivity and medical resource utilization of peginterferon alpha 2a vs the combination of interferon alpha 2b plus ribavirin as initial treatment in patients with chronic hepatitis C. J Viral Hepat 2004; 11:157-165.
20. Rustgi V, Brass C, Weng C. Improved health-related quality of life with pegylated interferon alfa-2b therapy in the treatment of chronic hepatitis C. Hepatology 2002; 36:573A.
21. Poynard T, McHutchison J, Manns M, et al. Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology 2002; 122:1303-1313.
22. Shiratori Y, Imazeki F, Moriyama M, et al. Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy. Ann Intern Med 2000; 132:517-524.
23. Chousterman M, Auray-Cartier V, Hagege H, et al. Efficacy of pegylated interferon alpha-2b in combination with ribavirin in patients with chronic hepatitis C non-responders to a previous treatment [abstract]. J Hepatol 2003; 38:133.
24. Diago M, Romero-Gomez M, Crespo J, et al. Peginterferon alfa-2a (Pegasys) and ribavirin (Copegus) in patients infected with HCV genotype 1 who failed to respond to interferon and ribavirin: final results of the Spanish high dose induction pilot trial [abstract]. Hepatology 2004; 40:389A.
25. Portal I, Botta-Fridlund D, Bourliere M, et al. Treatment with pegylated interferon alfa 2b in relapsers to standard interferon plus ribivirin in chronic hepatitis C: efficacy and safety results from a randomized multicentric French study [abstract]. Hepatology 2003; 38:311A.
26. Shiffman ML, Di Bisceglie AM, Lindsay KL, et al. Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment. Gastroenterology 2004; 126:1015-1023; discussion 947.
27. Deltenre P, Henrion J, Canva V, et al. Evaluation of amantadine in chronic hepatitis C: a meta-analysis. J Hepatol 2004; 41:462-473.
28. Hasan F, Al-Khaldi J, Asker H, et al. Peginterferon alpha-2b plus ribavirin with or without amantadine [correction of amantidine] for the treatment of non-responders to standard interferon and ribavirin. Antivir Ther 2004; 9:499-503.
29. Herrine SK, Brown RS, Jr., Bernstein DE, Ondovik MS, Lentz E, Te H. Peginterferon alpha-2a combination therapies in chronic hepatitis C patients who relapsed after or had a viral breakthrough on therapy with standard interferon alpha-2b plus ribavirin: a pilot study of efficacy and safety. Dig Dis Sci 2005; 50:719-726.
30. Younossi ZM, McCullough AC, Barnes DS, et al. Pegylated interferon alpha-2b, ribavirin and amantadine for chronic hepatitis C. Dig Dis Sci 2005; 50:970-975.
31. Jensen DM, Marcellin P. Rationale and design of the REPEAT study: a phase III, randomized, clinical trial of peginterferon alfa-2a (40 kDa) plus ribavirin in non-responders to peginterferon alfa-2b (12 kDa) plus ribavirin. Eur J Gastroenterol Hepatol 2005; 17:899-904.
32. Desombere I, Van Vlierberghe H, Couvent S, Clinckspoor F, Leroux-Roels G. Comparison of qualitative (COBAS AMPLICOR HCV 2.0 versus VERSANT HCV RNA) and quantitative (COBAS AMPLICOR HCV monitor 2.0 versus VERSANT HCV RNA 3.0) assays for hepatitis C virus (HCV) RNA detection and quantification: impact on diagnosis and treatment of HCV infections. J Clin Microbiol 2005; 43:2590-2597.
33. Swain M, Lai M-Y, Shiffman M, et al. Durability of sustained virological response (SVR) after treatment with peginterferon alfa-2a (40 KD) (PEGASYS®) alone or in combination with ribavirin (COPEGUS®): results of an ongoing long-term follow-up study. Hepatology 2004; 40(Suppl 1):400A. Abstract 543.
34. Davis GL, Wong JB, McHutchison JG, Manns MP, Harvey J, Albrecht J. Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatology 2003; 38:645-652.
35. Ferenci P, Fried MW, Shiffman ML, et al. Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin. J Hepatol 2005; 43:425-433.
36. Zeuzem S, Buti M, Ferenci P, et al. Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia. J Hepatol 2006; 44:97-103.
37. McHutchison JG, Manns M, Patel K, et al. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology 2002; 123:1061-1069.
38. Reddy KR, Hadziyannis SJ, Diago M, Marcellin P, Lopez-Talavera JC, Wrignt TL. The influence of cumulative peginterferon alfa 2a and ribavirin exposure on sustained virological response rates in patients with genotype 1 chronic hepatitis C [abstract]. J Hepatol 2005; 42:217.
39. Zeuzem S. Heterogeneous virologic response rates to interferon-based therapy in patients with chronic hepatitis C: who responds less well? Ann Intern Med 2004; 140:370-381.
40. McHutchison JG, Poynard T, Pianko S, et al. The impact of interferon plus ribavirin on response to therapy in black patients with chronic hepatitis C. The International Hepatitis Interventional Therapy Group. Gastroenterology 2000; 119:1317-1323.
41. Jeffers LJ, Cassidy W, Howell CD, Hu S, Reddy KR. Peginterferon alfa-2a (40 kd) and ribavirin for black American patients with chronic HCV genotype 1. Hepatology 2004; 39:1702-1708.
42. Foster GR, Fried MW, Hadziyannis SJ, Chaneac M. Treatment of chronic hepatitis C with peginterferon alfa-2a (40 KD) (PEGASYS®) and ribavirin (COPEGUS®): patient age has a marked influence on the individual estimated probability of achieving a sustained virological response. Hepatology 2003; 38(Suppl 1):246A. Abstract 189.
43. Swain M, Foster G, Fried M, et al. Clustering of poor prognostic factors in patients with chronic hepatitis C. J Hepatol 2005; 42(Suppl 2):221.
44. Torriani FJ, Rodriguez-Torres M, Rockstroh JK, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med 2004; 351:438-450.
45. Carrat F, Bani-Sadr F, Pol S, et al. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial. JAMA 2004; 292:2839-2848.
46. Hamano K, Sakamoto N, Enomoto N, et al. Mutations in the NS5B region of the hepatitis C virus genome correlate with clinical outcomes of interferon-alpha plus ribavirin combination therapy. J Gastroenterol Hepatol 2005; 20:1401-1409.
47. Poynard T, Bedossa P, Chevallier M, et al. A comparison of three interferon alfa-2b regimens for the long-term treatment of chronic non-A, non-B hepatitis. Multicenter Study Group. N Engl J Med 1995; 332:1457-1462.
48. Lee WM, Dienstag JL, Lindsay KL, et al. Evolution of the HALT-C trial: pegylated interferon as maintenance therapy for chronic hepatitis C in previous interferon nonresponders. Control Clin Trials 2004; 25:472-492.
49. Poynard T, Schiff E, Terg R, et al. Sustained virological response in the EPIC 3 trial: week twelve virology predicts SVR inprevious interferon/ribavirin failure receiving Peg-Intron/Rebetol (PR) weight based dosing (WBD) [abstract]. J Hepatol 2005; 42:40-1.
50. Pawlotsky JM, Dahari H, Neumann AU, et al. Antiviral action of ribavirin in chronic hepatitis C. Gastroenterology 2004; 126:703-714.
51. Bodenheimer HC, Jr., Lindsay KL, Davis GL, Lewis JH, Thung SN, Seeff LB. Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C: a multicenter trial. Hepatology 1997; 26:473-477.
52. Pol S, Nalpas B, Bourliere M, et al. Combination of ribavirin and interferon-alfa surpasses high doses of interferon-alfa alone in patients with genotype-1b-related chronic hepatitis C. Hepatology 2000; 31:1338-1344.
53. Manns MP. Adherence to combination therapy: influence on sustained virologie response and economic impact. Gastroenterol Clin North Am 2004; 33:511-24.
54. Crone C, Gabriel GM. Comprehensive review of hepatitis C for psychiatrists: risks, screening, diagnosis, treatment, and interferon-based therapy complications. J Psychiatr Pract 2003; 9:93-110.
55. Kraus MR, Schafer A, Csef H, Scheurlen M. Psychiatric side effects of pegylated interferon alfa-2b as compared to conventional interferon alfa-2b in patients with chronic hepatitis C. World J Gastroenterol 2005; 11:1769-1774.
56. Musselman DL, Lawson DH, Gumnick JF, et al. Paroxetine for the prevention of depression induced by high-dose interferon alfa. N Engl J Med 2001; 344:961-966.
57. Schaefer M, Schwaiger M, Garkisch AS, et al. Prevention of interferon-alpha associated depression in psychiatric risk patients with chronic hepatitis C. J Hepatol 2005; 42:793-798.
58. Ahern M, Imperial J, Lam S. Impact of a designated hepatology nurse on the clinical course and quality of life of patients treated with rebetron therapy for chronic hepatitis C. Gastroenterol Nurs 2004; 27:149-155.
59. Gujral H, Viscomi C, Collantes R. The role of physician extenders in managing patients with chronic hepatitis C. Cleve Clin J Med 2004; 71(Suppl 3):S33-37.
60. Pardo M, Castillo I, Navas S, Carreno V. Treatment of chronic hepatitis C with cirrhosis with recombinant human granulocyte colony-stimulating factor plus recombinant interferon-alpha. J Med Virol 1995; 45:439-44.
61. Collantes RS, Younossi ZM. The use of growth factors to manage the hematologic side effects of PEG-interferon alfa and ribavirin. J Clin Gastroenterol 2005; 39:59-13.
62. De Franceschi L, Fattovich G, Turrini F, et al. Hemolytic anemia induced by ribavirin therapy in patients with chronic hepatitis C virus infection: role of membrane oxidative damage. Hepatology 2000; 31:997-1004.
63. Kokinos J, Zacharakis G, Sidiopoulos J, Elefsiniotis J, Savvas S, Kountouras D. G-CSF is safe and improves adherence and SVR in HCV patients with genotype-1 who develop Peg-IFNa-2b related severe neutropenia. A multicenter study. J Hepatol 2006; 44:S200.
64. Afdhal NH. Role of epoetin alfa in maintaining ribavirin dose. Gastroenterol Clin North Am 2004; 33:525-35.
65. Dieterich DT, Wasserman R, Brau N, et al. Once-weekly epoetin alfa improves anemia and facilitates maintenance of ribavirin dosing in hepatitis C virus-infected patients receiving ribavirin plus interferon alfa. Am J Gastroenterol 2003; 98:2491-2499.
66. Pockros PJ, Shiffman ML, Schiff ER, et al. Epoetin alfa improves quality of life in anemic HCV-infected patients receiving combination therapy. Hepatology 2004; 40:1450-1458.
67. Lebray P, Nalpas B, Vallet-Pichard A, et al. The impact of haematopoietic growth factors on the management and efficacy of antiviral treatment in patients with hepatitis C virus. Antiviral Ther 2005; 10:769-776.
68. Zeuzem S, Hultcrantz R, Bourliere M, et al. Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3. J Hepatol 2004; 40:993-999.
69. Fattovich G, Pantalena M, Zagni I, Realdi G, Schalm SW, Christensen E. Effect of hepatitis B and C virus infections on the natural history of compensated cirrhosis: a cohort study of 297 patients. Am J Gastroenterol 2002; 97:2886-2895.
70. Planas R, Balleste B, Alvarez MA, et al. Natural history of decompensated hepatitis C virus-related cirrhosis. A study of 200 patients. J Hepatol 2004; 40:823-830.
71. Marcellin P, Brillanti S, Cheinquer H, et al. Peginterferon alfa-2a (40 KD) (Pegasys®) and ribavirin is an efficacious and safe treatment for chronic hepatitis C in patients with cirrhosis. Hepatology 2002; 36:576A. Abstract 1652.
72. Gross J, Johnson S, Kwo P, Afdhal N, Flamm S, Therneau T. Double dose of peginterferon alfa 2b with weight based ribavirin dose improves response for interferon/ribavirin non responders with hepatitis C: final results of RENEW. [abstract]. Hepatology 2005; 42:219A-220A.
73. Bressler BL, Guindi M, Tomlinson G, Heathcote J. High body mass index is an independent risk factor for non-response to antiviral treatment in chronic hepatitis C. Hepatology 2003; 38:639-644.
74. Okazaki T, Yoshihara H, Suzuki K, et al. Efficacy of interferon therapy in patients with chronic hepatitis C. Comparison between non-drinkers and drinkers. Scand J Gastroenterol 1994; 29:1039-1043.
75. Loguercio C, Di Pierro M, Di Marino MP, et al. Drinking habits of subjects with hepatitis C virus-related chronic liver disease: prevalence and effect on clinical, virological and pathological aspects. Alcohol Alcohol 2000; 35:296-301.
76. Ohnishi K, Matsuo S, Matsutani K, et al. Interferon therapy for chronic hepatitis C in habitual drinkers: comparison with chronic hepatitis C in infrequent drinkers. Am J Gastroenterol 1996; 91:1374-1379.
77. Tabone M, Sidoli L, Laudi C, et al. Alcohol abstinence does not offset the strong negative effect of lifetime alcohol consumption on the outcome of interferon therapy. J Viral Hepat 2002; 9:288-294.
78. Anand BS, Currie S, Dieperink E, et al. Alcohol use and treatment of hepatitis C virus: results of a national multicenter study. Gastroenterology 2006; 130:1607-1616.
79. Hickman IJ, Jonsson JR, Prins JB, et al. Modest weight loss and physical activity in overweight patients with chronic liver disease results in sustained improvements in alanine aminotransferase, fasting insulin, and quality of life. Gut 2004; 53:413-419.
80. Gitlin N, Muther K. Sustained viral response (SVR) with peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C (CHC) who were non responders (NR) to peginterferon alfa-2b and ribavirin. Hepatology 2004; 40(Suppl 1):343A. Abstract 413.
81. Mangia A, Ricci GL, Persico M, et al. A randomized controlled trial of pegylated interferon alpha-2a (40 KD) or interferon alpha-2a plus ribavirin and amantadine vs interferon alpha-2a and ribavirin in treatment-naive patients with chronic hepatitis C. J Viral Hepat 2005; 12:292-299.
82. Maynard M, Si Ahmed SN, Bailly F, et al. Retreatment of IFN/ribavirin non responder hepatitis C patients: benefit of peg-interferon/ribavirin/arnantadine [abstract]. Hepatology 2004; 40:398A.
83. Oguz D, Cicek B, Filik L, et al. Effect of interferon and ribavirin combined with amantadine in interferon and ribavirin non-responder patients with chronic hepatitis C (genotype 1). World J Gastroenterol 2005; 11:580-583.
84. Stauber RE, Hofer H, Hackl F, et al. Retreatment of patients with chronic hepatitis C not responding to interferon/ribavirin combination therapy with daily interferon plus ribavirin plus amantadine. Wien Klin Wochenschr 2004; 116:530-535.
85. Poo JL, Sanchez Tapias JM, Kershenobich D, et al. A pilot trial of thymalfasin (thymosin alpha-1) in combination with peginterferon alfa-2A and ribavirin in HCV non responders: 48 week results [abstract]. Hepatology 2004; 40:336A.
86. Poo JL, Sanchez-Avila F, Kershenobich D, Garcia-Samper X, Gongora J, Uribe M. Triple combination of thymalfasin, peginterferon alfa-2a and ribayirin in patients with chronic hepatitis C who have failed prior interferon and ribavirin treatment: 24-week interim results of a pilot study. J Gastroenterol Hepatol 2004; 19:579-81.
87. Leevy CB, Blatt L, Chalmers C. Interim results of a pilot study of the combination of type 1 (IFN alfacon) and type 2 (IFN gamma 1B) interferons in chronic hepatitis C patients who have failed to respond to PEG-interferon alfa2a plus ribavirin [abstract]. Hepatology 2004; 40:394A.
88. Heathcote EJ, Keeffe EB, Lee SS, et al. Re-treatment of chronic hepatitis C with consensus interferon. Hepatology 1998; 27:1136-1143.
89. Bocher WO, Schuchmann M, Link R, et al. Consensus interferon and ribavirin for patients with chronic hepatitis C and failure of previous interferon-alpha therapy. Liver Int 2006; 26:319-325.
90. Kaiser S, Hass HG, Gregor M. Successful retreatment of interferon/ribavirin nonresponders with daily dosing of consensus interferon. J Hepatol 2005; 42(suppl 2):207-208.
91. Cornberg M, Hadem J, Herrmann E, et al. Treatment with daily consensus interferon (CIFN) plus ribavirin in non-responder patients with chronic hepatitis C: a randomized open-label pilot study. J Hepatol 2006; 44:291-301.
92. Leevy CB, Chalmers C, Blatt L. Comparison of African-American and non-African-American patients' end of treatment response for PEG-IFN alpha 2a plus weight-based ribavirin non responders retreated with IFN Alfacon-1 plus weight-based ribavirin [abstract]. Hepatology 2004; 40:240A.
93. Afdhal N, Flamm S, Imperial JC, et al. Analyses of 40 kDa peginterferon alfa-2a (PEGASYS®) in combination with ribavirin, mycophenolate mofetil, amantadine, or amantadine plus ribavirin in patients that relapsed or did not respond to Rebetron™ therapy: a report of two randomized, multicenter, efficacy and safety studies. Hepatology 2001; 34:243A. Abstract 77.
94. Lodato F, Azzaroli F, Brillanti S, et al. Higher doses of peginterferon alpha-2b administered twice weekly improve sustained virological response in difficult-to-treat patients with chronic hepatitis C: results of a pilot randomized study. J Viral Hepat 2005; 12:536-542.
95. Berg T, von Wagner M, Nasser S, et al. Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin. Gastroenterology 2006; 130:1086-1097.
96. Sánchez-Tapias JM, Diago M, Escartín P, et al. Peginterferon-a2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment. Gastroenterology 2006; 131:451-460.
97. Marcellin P, Jensen D. Retreatment with Pegasys in patients not responding to prior peginterferon alfa 2b/ribavirin (RBV) combination therapy - efficacy analysis of the 12 week induction period of the REPEAT study. [abstract]. Hepatology 2005; 42:749A.
98. Lissen E, Clumeck N, Sola R, et al. Histological response to peginterferon alfa-2a (40 KD) (PEGASYS®) plus ribavirin (COPEGUS®) in patients with HIV-HCV co-infection: results of the AIDS PEGASYS Ribavirin International Co-infection Trial (APRICOT). Hepatology 2004; 40(Suppl 1):241A. Abstract 174.
99. Curry M, Cardenas A, Afdhal NH. Effect of maintenance peg-intron therapy on portal hypertension and its complications: results from the copilot study. J Hepatol 2005; 42(Suppl 2):A95.
100. Shiffman ML, Hofmann CM, Contos MJ, et al. A randomized, controlled trial of maintenance interferon therapy for patients with chronic hepatitis C virus and persistent viremia. Gastroenterology 1999; 117:1164-1172.
101. Angelico M, Cepparulo M, Barlattani A, et al. Unfavourable effects of colchicine in combination with interferon-alpha in the treatment of chronic hepatitis C. Aliment Pharmacol Ther 2000; 14:1459-1467.
102. Rambaldi A, Gluud C. Colchicine for alcoholic and non-alcoholic liver fibrosis and cirrhosis. Cochrane Database Syst Rev 2001:CD002148.
103. Arthur MJ. Matrix degradation in the liver. Semin Liver Dis 1990; 10:47-55.
104. Wu J, Danielsson A. Inhibition of hepatic fibrogenesis: a review of pharmacologic candidates. Scand J Gastroenterol 1994; 29:385-391.
105. Brenner DA, Alcorn JM. Therapy for hepatic fibrosis. Semin Liver Dis 1990; 10:75-83.
106. Nelson DR, Lauwers GY, Lau JY, Davis GL. Interleukin 10 treatment reduces fibrosis in patients with chronic hepatitis C: a pilot trial of interferon nonresponders. Gastroenteroloey 2000; 118:655-660.
107. Ideo G, Bellobuono A, Tempini S, et al. Antioxidant drugs combined with alpha-interferon in chronic hepatitis C not responsive to alpha-interferon alone: a randomized, multicentre study. Eur J Gastroenterol Hepatol 1999; 11:1203-1207.
108. Takagi H, Kakizaki S, Sohara N, et al. Pilot clinical trial of the use or alpha-tocopherol for the prevention of hepatocellular carcinoma in patients with liver cirrhosis. Int J Vitam Nutr Res 2003; 73:411-415.
109. Bhopale GM, Nanda RK. Emerging drugs for chronic hepatitis C. Hepatology Res 2005; 32:146-153.
110. Bain VG, Kaita KD, Yoshida EM, et al. A phase 2 study to evaluate the antiviral activity, response, safety, and pharmacokinetics of albumin-interferon alfa fusion protein in genotype 1 chronic hepatitis C patients. J Hepatol 2006; 44:671-678.
111. McHutchison JG, Shiffman ML, Cheung RC, et al. A randomized, double-blind, placebo-controlled dose-escalation trial of merimepodib (VX-497) and interferon-alpha in previously untreated patients with chronic hepatitis C. Antivir Ther 2005; 10:635-643.
112. Afdhal N, Rodriguez-Torres M, Lawitz E, et al. Enhanced antiviral efficacy for valopicitabine plus peg-interferon with hepatitis C patients with HCV genotype 1 infection: results of a phase IIa multicenter trial [abstract]. J Hepatol 2005; 42:39-40.
113. Chu H-M, McNair L. Results of a phase I single-dose escalation study of the hepatitis C protease inhibitor VX950 in healthy volunteers. Hepatology 2004; 40:735A.
114. Zeuzem S, Serrazin C, Wagner F, Rouzier R, Forestier N, Gupta S. The HCV NS3 protease inhibitor SCH503034 in combination with peg-IFNa non-responders: antiviral activity and HCV variant analysis. J Hepatol 2006; 44(Suppl 2):S35.
115. Weiland O, Fried M, Hadziyannis S, Messinger D, Freivogel K, Foster G. Peginterferon alpha-2a (40 kDa) plus ribavirin in treatment-naive patients with chronic hepatitis C and genotype 2 or 3 infection: individual estimated probability of sustained virological response. J Hepatol 2005; 42(Suppl 2):226.
116. Weiland O, Fried MW, Hadziyannis SJ, et al. Combination therapy with peginterferon alfa-2a (40 KD) (PEGASYS®) plus ribavirin (COPEGUS®) in treatment-naive patients with chronic hepatitis C and genotype 1 infection: individual estimated probability of sustained virological response (SVR). J Hepatol 2004; 40(Suppl 1):154.